Skip to main content
. Author manuscript; available in PMC: 2013 Dec 28.
Published in final edited form as: Anticancer Res. 2010 Apr;30(4):1279–1285.

Table I.

Characteristics of study population (n=118).

Median age (years) 50 (range:26–84)
Postmenopausal 54 (46%)
Median tumor size (cm) 2.2 (range:1–6)
Lymph node-positive 93 (79%)
ER/PR-positive 94 (80%)
 Adjuvant hormonal treatment 88 (94%)
 No adjuvant hormonal treatment 2 (2%)
 Adjuvant hormonal treatment unknown 4 (4%)
Her2-positive 26 (22%)
Recurrence 17 (14%)
Adjuvant chemotherapy
 Doxorubicin and cyclophosphamide 90 (76%)
 Additional taxane therapy 69 (58%)